DK1021534T3 - Hepatitis C-receptorprotein CD81 - Google Patents

Hepatitis C-receptorprotein CD81

Info

Publication number
DK1021534T3
DK1021534T3 DK98946642.0T DK98946642T DK1021534T3 DK 1021534 T3 DK1021534 T3 DK 1021534T3 DK 98946642 T DK98946642 T DK 98946642T DK 1021534 T3 DK1021534 T3 DK 1021534T3
Authority
DK
Denmark
Prior art keywords
hepatitis
receptor protein
protein
diagnosis
therapy
Prior art date
Application number
DK98946642.0T
Other languages
English (en)
Inventor
Sergio Abrignani
Guido Grandi
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9721182.5A external-priority patent/GB9721182D0/en
Priority claimed from GBGB9813560.1A external-priority patent/GB9813560D0/en
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1021534T3 publication Critical patent/DK1021534T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98946642.0T 1997-10-06 1998-10-06 Hepatitis C-receptorprotein CD81 DK1021534T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9721182.5A GB9721182D0 (en) 1997-10-06 1997-10-06 Hepatitis C receptor protein
GBGB9813560.1A GB9813560D0 (en) 1998-06-23 1998-06-23 Hepatitis C Receptor Protein
PCT/IB1998/001628 WO1999018198A1 (en) 1997-10-06 1998-10-06 Hepatitis c receptor protein cd81

Publications (1)

Publication Number Publication Date
DK1021534T3 true DK1021534T3 (da) 2010-02-01

Family

ID=26312375

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98946642.0T DK1021534T3 (da) 1997-10-06 1998-10-06 Hepatitis C-receptorprotein CD81

Country Status (13)

Country Link
US (4) US7097987B2 (da)
EP (1) EP1021534B1 (da)
JP (3) JP4198882B2 (da)
AT (1) ATE449847T1 (da)
AU (1) AU9363398A (da)
CA (1) CA2304796C (da)
CY (1) CY1109868T1 (da)
DE (1) DE69841322D1 (da)
DK (1) DK1021534T3 (da)
ES (1) ES2334727T3 (da)
HK (1) HK1025793A1 (da)
PT (1) PT1021534E (da)
WO (1) WO1999018198A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113914A1 (en) * 2001-12-10 2003-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of CD81 expression
US20020160936A1 (en) * 1999-09-29 2002-10-31 Howard J. Worman Hcv e2 protein binding agents for treatment of hepatitis c virus infection
GB9927320D0 (en) * 1999-11-18 2000-01-12 Chiron Spa Exosome separation
AU2229901A (en) * 1999-12-28 2001-07-09 Sumitomo Pharmaceuticals Company, Limited Preventives and remedies for chronic hepatitis
AU2001232267A1 (en) 2000-02-14 2001-08-20 Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases Remedies for hepatitis c
JP2001299140A (ja) * 2000-04-24 2001-10-30 Sumitomo Pharmaceut Co Ltd Ｈｃｖを増幅しうる細胞及び非ヒト動物
GB0016361D0 (en) 2000-07-03 2000-08-23 Chiron Spa Structure-based HCV drug design
US8039602B2 (en) * 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
WO2003014728A1 (fr) * 2001-08-10 2003-02-20 Mitsubishi Pharma Corporation Medicaments contre l'hepatite c
DK1662007T3 (da) * 2003-08-28 2011-06-14 Dainippon Sumitomo Pharma Co Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel
TW200813086A (en) * 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
NL2001318C2 (nl) 2008-02-25 2009-08-26 Schuitemaker Mach Bv Inrichting en werkwijze voor het snijden van kuilvoer.
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
CN104302667A (zh) 2011-12-26 2015-01-21 盐野义制药株式会社 外来体检测用单克隆抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500880A (ja) 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
US5631407A (en) * 1989-03-10 1997-05-20 The Trustees Of Columbia University In The City Of New York Transgenic mouse expressing DNA sequences encoding the human poliovirus receptor
JP2656995B2 (ja) 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
WO1991007489A1 (en) * 1989-11-22 1991-05-30 Childrens Hospital Of Los Angeles Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
GB9517926D0 (en) 1995-09-01 1995-11-01 Biocine Spa Binding protein
US6031088A (en) * 1996-05-23 2000-02-29 Albert Einstein College Of Medicine Of Yeshiva University Polycystic kidney disease PKD2 gene and uses thereof
US7491865B2 (en) * 2004-08-19 2009-02-17 Fred Hutchinson Cancer Research Center Mouse models of prostate cancer development and metastasis through expression of a hepsin transgene

Also Published As

Publication number Publication date
EP1021534A1 (en) 2000-07-26
JP4198882B2 (ja) 2008-12-17
US20090025098A1 (en) 2009-01-22
CA2304796A1 (en) 1999-04-15
CY1109868T1 (el) 2014-09-10
US20040258694A1 (en) 2004-12-23
EP1021534B1 (en) 2009-11-25
AU9363398A (en) 1999-04-27
WO1999018198A1 (en) 1999-04-15
US20070087407A1 (en) 2007-04-19
CA2304796C (en) 2013-12-03
JP2009035553A (ja) 2009-02-19
JP2001519150A (ja) 2001-10-23
PT1021534E (pt) 2010-03-03
HK1025793A1 (en) 2000-11-24
ES2334727T3 (es) 2010-03-15
US7097987B2 (en) 2006-08-29
US20120066779A1 (en) 2012-03-15
ATE449847T1 (de) 2009-12-15
JP2012125246A (ja) 2012-07-05
DE69841322D1 (de) 2010-01-07

Similar Documents

Publication Publication Date Title
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
TR200000913T2 (tr) Tıbbi maddeler
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
DE60033649D1 (de) Verbindungen und therapeutische methoden
MXPA02008239A (es) Gen humano de la esquizofrenia.
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos
PL400309A1 (pl) Kwasy nukleinowe, proteiny oraz przeciwciala BTL-II
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
PT1196188E (pt) Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv